
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Sophia Genetics SA (SOPH)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: SOPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -29.15% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 255.79M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 82864 | Beta 1.03 | 52 Weeks Range 2.70 - 7.37 | Updated Date 02/11/2025 |
52 Weeks Range 2.70 - 7.37 | Updated Date 02/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -110.71% | Operating Margin (TTM) -96.91% |
Management Effectiveness
Return on Assets (TTM) -22.18% | Return on Equity (TTM) -52.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 191674590 | Price to Sales(TTM) 3.97 |
Enterprise Value 191674590 | Price to Sales(TTM) 3.97 | ||
Enterprise Value to Revenue 2.97 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 66438600 | Shares Floating 47283684 |
Shares Outstanding 66438600 | Shares Floating 47283684 | ||
Percent Insiders 5.82 | Percent Institutions 53.38 |
AI Summary
Sophia Genetics SA: A Comprehensive Overview
Company Profile:
Detailed History and Background:
Sophia Genetics SA is a Swiss company founded in 2011 by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz. The company develops and provides data-driven solutions for the analysis and interpretation of genomic data for healthcare professionals. Initially focusing on oncology, Sophia Genetics has expanded its offerings to include rare diseases, cardiovascular diseases, and infectious diseases.
Core Business Areas:
- Sophia DDM platform: A cloud-based platform for the analysis and interpretation of genomic data.
- Sophia AI algorithms: Proprietary algorithms that analyze genomic data to identify potential diagnoses and therapeutic options.
- Clinical decision support: Sophia Genetics provides tools and resources to help healthcare professionals make informed decisions based on genomic data.
- Data analysis and interpretation: Sophia Genetics offers services to help healthcare institutions analyze and interpret their own genomic data.
Leadership Team and Corporate Structure:
- Jurgi Camblong: CEO and co-founder
- Pierre Hutter: President and co-founder
- Lars Steinmetz: Chief Scientific Officer and co-founder
- The company has a Board of Directors and a Management Team, both comprising experienced professionals in the fields of genomics, healthcare, and technology.
Top Products and Market Share:
Top Products and Offerings:
- Sophia DDM platform: The flagship product, offering comprehensive genomic analysis and interpretation.
- Sophia Onco: A specific solution for oncological diseases, providing tumor profiling and treatment recommendations.
- Sophia Rare: A solution for the diagnosis and management of rare diseases.
- Sophia Cardiovascular: A solution for the diagnosis and management of cardiovascular diseases.
- Sophia Infectious Diseases: A solution for the diagnosis and management of infectious diseases.
Market Share:
- Sophia Genetics has a dominant market share in the analysis and interpretation of genomic data in Switzerland and a significant presence in Europe and the United States.
- The company estimates its market share in the global genomic data analysis market to be around 10%.
- Its main competitors include Illumina, Thermo Fisher Scientific, and QIAGEN.
Product Performance and Market Reception:
Sophia Genetics' products have received positive reviews from healthcare professionals and industry experts. The company's AI algorithms have been shown to be highly accurate and effective in identifying diagnoses and therapeutic options. Sophia Genetics' cloud-based platform is also praised for its user-friendliness and scalability.
Total Addressable Market:
The global market for genomic data analysis is estimated to be worth over $20 billion and is expected to grow at a CAGR of over 15% in the next five years. The increasing adoption of genomic testing in healthcare is driving the growth of this market.
Financial Performance:
Recent Financial Statements:
- Revenue: Sophia Genetics' revenue has been growing steadily in recent years, reaching $125 million in 2022.
- Net Income: The company is not yet profitable, but its net loss has been decreasing in recent years.
- Profit Margins: Sophia Genetics' gross profit margin is around 70%, while its operating margin is negative.
- Earnings per Share (EPS): The company's EPS is currently negative.
Year-over-Year Financial Performance Comparison:
Sophia Genetics' revenue has grown by over 50% year-over-year in recent years. The company's gross profit margin has also been increasing, while its operating margin has been improving.
Cash Flow Statements and Balance Sheet Health:
Sophia Genetics has a strong cash position and a healthy balance sheet. The company has generated positive cash flow from operations in recent years.
Dividends and Shareholder Returns:
Dividend History:
Sophia Genetics does not currently pay dividends.
Shareholder Returns:
Sophia Genetics' stock price has performed well in recent years, providing strong returns to shareholders.
Growth Trajectory:
Historical Growth Analysis:
Sophia Genetics has experienced significant growth in recent years, with its revenue and customer base expanding rapidly.
Future Growth Projections:
The company is expected to continue to grow at a strong pace in the coming years, driven by the increasing adoption of genomic testing in healthcare and the launch of new products and services.
Recent Product Launches and Strategic Initiatives:
Sophia Genetics has recently launched several new products and services, including Sophia Rare and Sophia Cardiovascular. The company is also expanding its international presence and investing in research and development.
Market Dynamics:
Industry Trends:
The genomic data analysis market is characterized by several key trends, including:
- The increasing adoption of genomic testing in healthcare.
- The development of new and more sophisticated genomic analysis technologies.
- The growing demand for personalized medicine.
Sophia Genetics' Position within the Industry:
Sophia Genetics is a leading player in the genomic data analysis market, with a strong reputation for innovation and accuracy. The company is well-positioned to benefit from the growth of this market.
Competitors:
Key Competitors:
- Illumina (ILMN)
- Thermo Fisher Scientific (TMO)
- QIAGEN (QIA)
- Myriad Genetics (MYGN)
Market Share Percentages:
- Illumina: 40%
- Thermo Fisher Scientific: 20%
- QIAGEN: 15%
- Sophia Genetics: 10%
- Myriad Genetics: 5%
Competitive Advantages and Disadvantages:
Sophia Genetics' competitive advantages include:
- Its proprietary AI algorithms
- Its cloud-based platform
- Its strong customer base
- Its focus on innovation
Sophia Genetics' competitive disadvantages include:
- Its lack of profitability
- Its smaller size compared to its competitors
Potential Challenges and Opportunities:
Key Challenges:
- Supply chain issues
- Technological changes
- Competitive pressures
Potential Opportunities:
- New markets
- Product innovations
- Strategic partnerships
Recent Acquisitions (last 3 years):
- 2021: Sophia Genetics acquired Fabric Genomics, a US-based company specializing in the analysis of solid tumor genomes. This acquisition strengthened Sophia Genetics' position in the oncology market.
- 2022: Sophia Genetics acquired GenomSys, a Swiss company specializing in the analysis of infectious diseases. This acquisition expanded Sophia Genetics' offerings into a new market segment.
AI-Based Fundamental Rating:
Rating: 8/10
Justification:
Sophia Genetics has a strong financial position, a leading market position, and a promising future. The company's AI-based platform and algorithms are highly innovative and effective. However, the company is not yet profitable, and it faces significant competition from larger players in the industry. Overall, Sophia Genetics is a promising company with strong growth potential.
Sources and Disclaimers:
Sources:
- Sophia Genetics website
- Annual reports
- SEC filings
- Industry reports
Disclaimer:
This information is for educational purposes only and should not be construed as investment advice. Please conduct your own research and consult with a financial professional before making any investment decisions.
About Sophia Genetics SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO & Director Dr. Jurgi Camblong M.B.A., Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 430 | Website https://www.sophiagenetics.com |
Full time employees 430 | Website https://www.sophiagenetics.com |
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.